Ceplene’s Cost Effectiveness Proved for UK AML Patients

25 October 2009 (Last Updated October 25th, 2009 18:30)

EpiCept has announced new findings demonstrating the cost effectiveness of using Ceplene for the remission maintenance of acute myeloid leukaemia (AML) patients in first remission in the UK. Researchers from Applied Healthcare Resource Management analysed data from the Phase III clinical

EpiCept has announced new findings demonstrating the cost effectiveness of using Ceplene for the remission maintenance of acute myeloid leukaemia (AML) patients in first remission in the UK.

Researchers from Applied Healthcare Resource Management analysed data from the Phase III clinical trial to determine the incremental cost effectiveness of Ceplene in the UK.

According to the researchers, the expected cost for the UK healthcare system to administer Ceplene to all eligible AML patients is approximately £24.1m per year with annual savings due to decreased relapse events ranging from £2.5m to £3.5m.

The study found that the budget impact to adopt Ceplene for AML is well within the established per-patient reimbursement threshold for a new drug.